Previous Article | Next Article ![]()
Infection and Immunity, October 2000, p. 6062-6065, Vol. 68, No. 10
Division of Virulence Assessment, Center for
Food Safety and Applied Nutrition, Food and Drug Administration,
Washington, D.C. 20204
Received 1 May 2000/Returned for modification 16 June 2000/Accepted 27 July 2000
Cholera vaccines developed by the deletion of CTX genes from
Vibrio cholerae induce a residual reactogenicity in up to
10% of vaccinees. A novel cytotonic agent named secreted CHO cell elongating protein (S-CEP) was purified from culture supernatants of
CVD 103-HgR (Levine et al., Lancet ii:467-470, 1988). Five fractionation steps yielded electrophoretically pure S-CEP with an
Mr of 79,000. A partially purified preparation
caused fluid accumulation in the sealed infant mouse model. The amino
terminus bore a unique sequence with strong homology to a cytotonic
toxin of El Tor V. cholerae.
0019-9567/00/$04.00+0
Purification and Characterization of a Cytotonic
Protein Expressed In Vitro by the Live Cholera Vaccine Candidate
CVD 103-HgR
*
Corresponding author. Mailing address: Food and Drug
Administration, CFSAN/DVA/HFS 327, Washington, DC 20204. Phone: (202) 205-4918. Fax: (202) 205-4939. E-mail:
rhh{at}cfsan.fda.gov.
| J. Bacteriol. | J. Virol. | Eukaryot. Cell |
|---|
| Microbiol. Mol. Biol. Rev. | Clin. Vaccine Immunol. | All ASM Journals |
|---|